<DOC>
	<DOCNO>NCT01150565</DOCNO>
	<brief_summary>The purpose study primarily evaluate safety tolerability two dose level investigational drug-delivery system ( LiRIS ) patient moderate severe symptom interstitial cystitis .</brief_summary>
	<brief_title>Safety Study LiRIS Interstitial Cystitis ( IC ) Patients</brief_title>
	<detailed_description>Approximately 20 female patient interstitial cystitis enrol study multiple center Canada . LiRIS develop provide drug therapy directly urinary bladder . LiRIS contain Lidocaine , market drug ( approve Health Canada ) commonly use local ( skin oral ) anaesthesia . LiRIS design release control amount lidocaine bladder 2 week period . Two dose group approximately 10 patient per group enrol study ; first group patient receive low dose LiRIS , second group receive high dose LiRIS . All patient receive LiRIS treatment 14 day , clinic follow-up 7 14 day treatment . Additional telephone follow-up occur approximately 6 10 week LiRIS treatment . The maximum duration participation , include screen period 14 day , 104 day .</detailed_description>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<criteria>Female patient â‰¥ 18 year age If childbearing potential , agree use effective contraception define protocol Capable understand complete symptom diary questionnaire require study Diagnosed IC , define protocol criterion Bladder urethra anatomical feature , opinion investigator , might prevent safe placement , indwell use , removal LiRIS History presence medical condition would interfere ability ass symptom Pregnant lactating patient</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>